Bayer's investment arm Leaps by Bayer is investing in Khloris, a company looking to use stem cell-based vaccines to prevent and treat cancer.
Assistant Professor of Genetics and Developmental Biology Stormy Chamberlain holds a tray of stem cells at the University of Connecticut`s Stem Cell Institute at the UConn Health Center .Pharmaceutical giant Bayer just made an investment through its investment arm Leaps by Bayer in Khloris, a company looking to use stem cell-based vaccines to prevent and treat cancer.
Khloris is working to see if it's possible to reintroduce stem cells — cells that aren't yet specialized — into the body to jump-start the immune system and knock out a person's cancer, or prevent a particular cancer from occurring in the first place. Juergen Eckhardt, who heads up Leaps by Bayer, told Business Insider that the hope is to get the treatment into human trials in 2020.
Bayer is making a bet that an experimental kind of vaccine could one day treat or maybe even prevent cancer., the investment arm within the life sciences and pharmaceutical giant that's focused on finding and funding breakthroughs, just made an investment in Khloris, a company founded in 2017 using technology spun out of Stanford University to explore the use of stem cells as a way to one day treat or prevent cancer. The financial terms of the investment were not disclosed.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Amid the opioid scandal, what next for Purdue Pharma and the Sackler family?Our weekly podcast on the markets, the economy and the world of business
Read more »
AstraZeneca inks $6.9 billion cancer drug pact with Japanese pharma firm Daiichi SankyoAstraZeneca and Japan's Daiichi Sankyo signed a potential multibillion-dollar deal to develop and sell Daiichi's cancer drug trastuzumab deruxtecan.
Read more »
N.Y. accuses opioid maker Purdue of illegal fund transfers to SacklersPurdue Pharma LP fraudulently transferred funds to members of the wealthy Sackle...
Read more »
New York AG sues Purdue Pharma, J&J, McKesson in case against opioid manufacturers and distributorsThe New York Attorney General is filing new allegations against Purdue Pharma and the Sackler Family, according to The Wall Street Journal.
Read more »
OxyContin-maker Purdue Pharma and Sackler family agree to pay $270 million to settle opioid caseThe case against Purdue and other manufacturers was scheduled to go to trial in May. Accusations against the Stamford, Connecticut-based company included downplaying the addiction risk of opioids while overstating the benefits.
Read more »
With $270 million settlement, Purdue Pharma starts paying for the opioid crisisOn a new Post Reports: katiezez on a big blow for opioid maker Purdue Pharma, AmyEGardner on Florida’s amendment giving felons the right to vote, and MrDanZak on how monarch butterflies, climate change and immigration are connected.
Read more »
Purdue Pharma agrees to $270 million settlement in Oklahoma opioid casePurdue Pharma agrees to $270 million settlement in Oklahoma opioid case via ReutersTV
Read more »
OxyContin maker Purdue Pharma reaches $270 million settlement related to opioid crisisOxyContin maker Purdue Pharma reaches $270 million settlement related to opioid crisis, with $200 million earmarked for an opioid center at Oklahoma State University.
Read more »